Therapeuticsmd, Inc. is a US-listed company in the pharmaceuticals industry. Its financial year ends in December.
Loading chart…
Third-party market data · may be delayed
Under review: every model's value for Therapeuticsmd, Inc. is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.
Under review: free cash flow after stock pay is not positive. We'll show the comparison once resolved.
Therapeuticsmd, Inc. valuation: adjust assumptions and compare models →
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
Therapeuticsmd has little or no product revenue yet. It passes 2 of our 2 financial-health checks.
Our model value for Therapeuticsmd is under review, so past values are not shown until it is resolved.
Source: 10-Q filed August 11, 2026 on SEC EDGAR · Financials · Valuation
Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.
Therapeuticsmd, Inc.'s trailing-twelve-month revenue grew 27.8% year on year, with a free-cash-flow margin of 94.7%. Where it stands out: free-cash-flow margin of 94.7% ranks 2 of 74 pharmaceuticals companies we cover. Where it lags: change in growth rate of -54.3pp ranks 69 of 74 pharmaceuticals companies we cover.
Current signal Free cash flow diverging from earnings: TTM free cash flow grew 201.9% while net income grew 52.7%: a 149pp divergence.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Loading chart…
Third-party market data · may be delayed
Company announcements, filed results and changes that matter to shareholders.
The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.
We value Therapeuticsmd, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.1%: the 10-year Treasury yield (4.9%) plus a beta of 0.93 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | ~$19 ~$13–$28 | Left out: out of range vs price (10.60x) |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | ~$9.7 ~$8.3–$12 | Left out: out of range vs price (5.37x) |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. | — | Combined value withheld. Review the individual models and their assumptions. |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Therapeuticsmd, Inc. with Pharmaceuticals in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
| At fiscal year end | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Share price | $518.50 | $288.50 | $302.00 | $190.50 | $121.00 | $60.50 | $18.00 | $5.59 | $2.25 | $0.86 | $1.63 |
| Market value | $1.8bn | $1.1bn | $1.2bn | $857m | $596m | $334m | $143m | $52m | $23m | $10m | $19m |
| + Net debt (− = net cash) | $0 | −$132m | −$127m | −$88m | $34m | $157m | $123m | −$49m | −$4m | −$5m | −$7m |
| Enterprise value | $1.8bn | $1000m | $1.1bn | $769m | $630m | $491m | $267m | $3m | $19m | $5m | $11m |
| Multiples | |||||||||||
| Price / sales | 89.2x | 58.5x | 74.0x | 53.3x | 12.0x | 5.1x | 55.7x | 0.7x | 18.0x | 5.6x | 6.2x |
| Price / earnings | — | — | — | — | — | — | — | 0.5x | — | — | — |
| Price / free cash flow | — | — | — | — | — | — | — | 5.6x | — | 8.5x | 7.7x |
| EV / EBITDA | — | — | — | — | — | — | — | 1.3x | — | — | — |
Weak moat
How hard Therapeuticsmd's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.
Cash operating profit has been a median -36.2% of total assets over 9 years.
Gross margin has been a median 78.1%, moving by 7.9 percentage points (standard deviation) across 10 years.
Operating margin has been a median -232.8%; its worst year was -818.9%.
Free cash flow was positive in 3 of 10 years, at a median -241.5% of revenue.
The diluted share count rose 140.2% over five years; stock-based pay has been a median 19.1% of revenue.
AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (27 before it).
No analyst estimates are published for Therapeuticsmd, Inc.: too few analysts cover it.
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2023 | −$0.07 | −$0.24 | −242.9% |
| Mar 2023 | $0.06 | −$0.24 | −500.0% |
| Dec 2022 | −$1.11 | $8.23 | +841.4% |
| Sept 2022 | −$2.04 | −$3.13 | −53.4% |
Adjusted EPS as companies report it, against the average analyst estimate.
Last 12 months +52.1%
| Part | Then | Now | Effect |
|---|---|---|---|
| Revenue (last 12 months) | $3m | $3m | +27.8% |
| P/S multiple | 5.4x | 6.4x | +19.7% |
| Share count | 12m | 12m | −0.5% |
Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.
Last 3 years −18.1%
| Part | Then | Now | Effect |
|---|---|---|---|
| Revenue (last 12 months) | $70m | $3m | −95.3% |
| P/S multiple | 0.3x | 6.4x | +1924.8% |
| Share count | 10m | 12m | −13.7% |
Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.
| Calendar year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 to date |
|---|---|---|---|---|---|---|
| Return | ||||||
| TXMD | −70% | −69% | −60% | −62% | +90% | +11% |
| Industry peers (median) | −18% | −49% | −13% | −2% | +7% | −14% |
| S&P 500 | +29% | −18% | +26% | +25% | +18% | +11% |
| Months that ended higher | ||||||
| TXMD | 8% | 33% | 17% | 42% | 42% | 64% |
| S&P 500 | 75% | 42% | 67% | 75% | 75% | 46% |
| Largest fall from a high during the year | ||||||
| TXMD | −86% | −91% | −68% | −68% | −54% | −36% |
| S&P 500 | −5% | −25% | −10% | −8% | −19% | −9% |
Worst fall since October 29, 2015: 100% from December 29, 2015 to March 14, 2025. Getting back needed a 75243% gain, and the shares have not yet recovered.
| Results released | Next day | S&P 500 next day | 5 days | 21 days |
|---|---|---|---|---|
| August 11, 2026 | +0.5% | −0.1% | −2.9% | +1.4% |
| May 12, 2026 | +3.1% | +0.4% | +4.1% | −7.1% |
| March 30, 2026 | −3.8% | +2.6% | −3.8% | +0.5% |
| November 13, 2025 | +16.7% | −1.7% | +14.3% | +1.2% |
| August 12, 2025 | +7.4% | +1.4% | +7.4% | +2.8% |
| May 13, 2025 | −1.4% | +0.8% | +0.7% | −18.9% |
| March 27, 2025 | −3.0% | −2.3% | −4.0% | +20.8% |
| November 12, 2024 | −1.3% | −0.3% | −14.5% | −17.8% |
| August 12, 2024 | −1.2% | +1.7% | −4.6% | +2.9% |
| May 10, 2024 | +2.5% | +0.1% | +9.4% | +2.5% |
| March 29, 2024 | +1.3% | −0.2% | −3.5% | −17.5% |
| November 14, 2023 | +16.8% | +2.2% | +38.1% | +18.3% |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | Revenue (TTM) |
|---|---|
| FY23 Q3 | $69.4M |
| FY23 Q4 | $1.3M |
| FY24 Q1 | $1.2M |
| FY24 Q2 | $996K |
| FY24 Q3 | $1.6M |
| FY24 Q4 | $1.8M |
| FY25 Q1 | $1.8M |
| FY25 Q2 | $2.6M |
| FY25 Q3 | $2.8M |
| FY25 Q4 | $3M |
| FY26 Q1 | $3.4M |
| FY26 Q2 | $3.3M |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | Revenue growth, TTM YoY |
|---|---|
| FY23 Q3 | 3.6% |
| FY23 Q4 | -98.9% |
| FY24 Q1 | -98.8% |
| FY24 Q2 | -98.6% |
| FY24 Q3 | -97.7% |
| FY24 Q4 | 35.3% |
| FY25 Q1 | 53.5% |
| FY25 Q2 | 156.9% |
| FY25 Q3 | 75.2% |
| FY25 Q4 | 71.6% |
| FY26 Q1 | 82.1% |
| FY26 Q2 | 27.8% |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | Operating margin (TTM) |
|---|---|
| FY23 Q3 | 59.9% |
| FY23 Q4 | -654.6% |
| FY24 Q1 | -583.7% |
| FY24 Q2 | -734.4% |
| FY24 Q3 | -418.3% |
| FY24 Q4 | -324.6% |
| FY25 Q1 | -318.1% |
| FY25 Q2 | -147.0% |
| FY25 Q3 | -124.8% |
| FY25 Q4 | -145.3% |
| FY26 Q1 | -114.3% |
| FY26 Q2 | -120.9% |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | FCF margin (TTM) |
|---|---|
| FY23 Q3 | 79.4% |
| FY23 Q4 | -1772.7% |
| FY24 Q1 | -1218.4% |
| FY24 Q2 | -980.3% |
| FY24 Q3 | -238.5% |
| FY24 Q4 | 66.4% |
| FY25 Q1 | 114.0% |
| FY25 Q2 | 40.1% |
| FY25 Q3 | 75.0% |
| FY25 Q4 | 81.2% |
| FY26 Q1 | 80.5% |
| FY26 Q2 | 94.7% |
| Fiscal year | 2011 Dec 2011 | 2012 Dec 2012 | 2013 Dec 2013 | 2014 Dec 2014 | 2015 Dec 2015 | 2016 Dec 2016 | 2017 Dec 2017 | 2018 Dec 2018 | 2019 Dec 2019 | 2020 Dec 2020 | 2021 Dec 2021 | 2022 Dec 2022 | 2023 Dec 2023 | 2024 Dec 2024 | 2025 Dec 2025 | LTM Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income | ||||||||||||||||
| Revenue | 2 | 4 | 9 | 15 | 20 | 19 | 17 | 16 | 50 | 65 | 3 | 70 | 1 | 2 | 3 | 3 |
| Gross profit | 1 | 2 | 7 | 11 | 16 | 15 | 14 | 13 | 43 | 49 | 1 | 69 | 1 | — | — | — |
| EBITDA | −5 | −16 | −26 | −54 | −85 | −90 | −77 | −130 | −150 | −151 | −79 | 2 | −8 | −6 | −4 | −4 |
| Operating income | −5 | −16 | −26 | −54 | −85 | −90 | −78 | −130 | −151 | −156 | −80 | 1 | −9 | −6 | −4 | −4 |
| Net income | −13 | −35 | −28 | −54 | −85 | −90 | −77 | −133 | −176 | −184 | −172 | 112 | −10 | −2 | −1 | −0 |
| Diluted EPS | −$0.21 | −$0.38 | −$0.22 | −$0.36 | −$0.49 | −$0.46 | −$0.37 | −$0.59 | −$0.72 | −$0.67 | −$21.66 | $11.96 | −$0.99 | −$0.19 | −$0.05 | — |
| Growth (year on year) | ||||||||||||||||
| Revenue | — | +82.8% | +129.8% | +71.2% | +34.1% | −3.9% | −13.3% | −4.0% | +208.4% | +30.7% | −96.0% | +>999% | −98.1% | +35.3% | +71.6% | +27.8% |
| EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | −418.8% | — | — | — |
| Net income | — | — | — | — | — | — | — | — | — | — | — | — | −109.2% | — | — | — |
| Diluted EPS | — | — | — | — | — | — | — | — | — | — | — | — | −108.3% | — | — | — |
| Margins | ||||||||||||||||
| Gross margin | 54.6% | 64.7% | 77.7% | 75.6% | 77.6% | 78.4% | 84.3% | 83.0% | 87.2% | 75.4% | 45.5% | 98.0% | 100.0% | — | — | — |
| EBITDA margin | −257.3% | −421.5% | −293.4% | −359.3% | −422.6% | −465.6% | −461.4% | −807.0% | −301.8% | −233.5% | <−999% | 3.4% | −583.8% | −318.2% | −132.6% | −109.2% |
| Operating margin | −259.9% | −423.0% | −294.1% | −359.6% | −422.9% | −466.3% | −462.7% | −808.8% | −304.6% | −239.8% | <−999% | 1.7% | −654.6% | −347.1% | −145.3% | −120.9% |
| Net margin | −618.4% | −919.9% | −323.8% | −360.8% | −422.4% | −464.3% | −458.5% | −823.7% | −354.8% | −282.9% | <−999% | 160.1% | −789.4% | −123.9% | −18.8% | −6.6% |
| Free-cash-flow margin | −239.2% | −335.4% | −237.1% | −303.1% | −393.2% | −359.3% | −454.3% | −664.8% | −338.7% | −246.1% | <−999% | 13.4% | <−999% | 66.4% | 81.2% | 94.7% |
| Cash flow | ||||||||||||||||
| Cash from operations | −5 | −13 | −21 | −46 | −79 | −69 | −76 | −107 | −166 | −159 | −143 | 9 | −23 | 1 | 2 | 3 |
| Capital spending | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | −5 | −13 | −21 | −46 | −79 | −70 | −76 | −107 | −168 | −160 | −143 | 9 | −23 | 1 | 2 | 3 |
| Stock-based pay | 0 | 2 | 4 | 5 | 7 | 17 | 7 | 9 | 11 | 11 | 18 | 12 | 1 | 0 | 0 | 0 |
| Free cash flow after stock pay | −5 | −15 | −25 | −51 | −86 | −87 | −83 | −116 | −179 | −170 | −161 | −2 | −24 | 1 | 2 | 3 |
| Balance sheet | ||||||||||||||||
| Cash | 0 | — | — | — | — | 132 | 127 | 162 | 161 | 80 | 65 | 49 | 4 | 5 | 7 | 9 |
| Total debt | 0 | 4 | — | 0 | 0 | 0 | 0 | 73 | 195 | 238 | 188 | — | 0 | 0 | 0 | 0 |
| Net debt (negative = net cash) | −0 | — | — | — | — | −132 | −127 | −88 | 34 | 157 | 123 | −49 | −4 | −5 | −7 | −9 |
| Diluted shares | 1m | 2m | 3m | 3m | 3m | 4m | 4m | 5m | 5m | 6m | 8m | 9m | 10m | 12m | 12m | — |
| Quarter | 2024 Q3 Sept 2024 | 2024 Q4 Dec 2024 | 2025 Q1 Mar 2025 | 2025 Q2 Jun 2025 | 2025 Q3 Sept 2025 | 2025 Q4 Dec 2025 | 2026 Q1 Mar 2026 | 2026 Q2 Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Income | ||||||||
| Revenue | 547 | 667 | 393 | 952 | 784 | 893 | 724 | 869 |
| EBITDA | −1,038 | −552 | −1,186 | −599 | −766 | −1,455 | −629 | −721 |
| Operating income | −1,134 | −652 | −1,281 | −695 | −862 | −1,552 | −723 | −816 |
| Net income | −609 | 252 | −653 | 551 | 152 | −619 | 95 | 155 |
| Diluted EPS | −$0.05 | $0.02 | −$0.06 | $0.05 | $0.01 | −$0.05 | $0.01 | $0.01 |
| Growth (year on year) | ||||||||
| Revenue | — | +32.9% | +25.6% | +306.8% | +43.3% | +33.9% | +84.2% | −8.7% |
| Net income | — | — | — | — | — | −345.6% | — | −71.9% |
| Diluted EPS | — | — | — | — | — | −350.0% | — | −80.0% |
| Margins | ||||||||
| EBITDA margin | −189.8% | −82.8% | −301.8% | −62.9% | −97.7% | −162.9% | −86.9% | −83.0% |
| Operating margin | −207.3% | −97.8% | −326.0% | −73.0% | −109.9% | −173.8% | −99.9% | −93.9% |
| Net margin | −111.3% | 37.8% | −166.2% | 57.9% | 19.4% | −69.3% | 13.1% | 17.8% |
| Free-cash-flow margin | −13.0% | 2.5% | 177.9% | 40.0% | 127.4% | 42.0% | 130.4% | 89.6% |
| Cash flow | ||||||||
| Cash from operations | −71 | 17 | 699 | 381 | 999 | 375 | 944 | 779 |
| Capital spending | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | −71 | 17 | 699 | 381 | 999 | 375 | 944 | 779 |
| Stock-based pay | 33 | 24 | 23 | 1 | 0 | 51 | 2 | 4 |
| Free cash flow after stock pay | −104 | −7 | 676 | 380 | 999 | 324 | 942 | 775 |
| Last 12 months unless stated | TXMD | EYPT | CPHI | NTRB | LPCN | SXTC | Median |
|---|---|---|---|---|---|---|---|
| Revenue, last 12 months | $3m | $3m | $4m | $2m | $2m | $1m | $276m |
| Revenue growth, last 12 months | 27.8% | −94.6% | −11.0% | −37.3% | −62.7% | −34.6% | 9.9% |
| Revenue growth, 3-year average | −63.9% | −57.9% | −21.0% | −10.8% | 205.6% | — | 5.5% |
| Revenue growth, latest quarter | −8.7% | −90.5% | −7.5% | −29.7% | −69.5% | — | 6.5% |
| Gross margin | 100.0% | — | 11.8% | 33.1% | — | 21.9% | 62.0% |
| Operating margin | −120.9% | <−999% | −111.8% | −435.6% | −800.8% | −625.9% | −5.9% |
| Operating margin, 3-year average | −334.1% | <−999% | −87.7% | −396.6% | −378.5% | −267.4% | −7.4% |
| Net margin | −6.6% | <−999% | −114.3% | −430.4% | −755.1% | −545.2% | −7.3% |
| Cash from operations / revenue | 94.7% | <−999% | −3.6% | −224.5% | −713.0% | −353.0% | 10.2% |
| Free-cash-flow margin | 94.7% | <−999% | −49.2% | −224.5% | −713.0% | −353.0% | 8.6% |
| Free-cash-flow margin, 3-year average | −281.8% | <−999% | −16.3% | −217.5% | −309.9% | −126.6% | 7.4% |
| Stock pay / revenue | 1.7% | >999% | 0.7% | 65.9% | 14.6% | 466.2% | 3.6% |
| Change in share count | 18.0% | 4.2% | 6.8% | 8.9% | 25.2% | >999% | 1.9% |
| Measure | Company | Peer median | Rank |
|---|---|---|---|
| Revenue growth Growth | 27.8% | 10.0% | 16 of 74 |
| Change in growth rate Growth | -54.3pp | -0.3pp | 69 of 74 |
| Operating margin Profitability | -120.9% | -5.9% | 57 of 67 |
| Net margin Profitability | -6.6% | -7.3% | 37 of 75 |
| Free-cash-flow margin Cash generation | 94.7% | 10.1% | 2 of 74 |
| Stock pay as % of revenue Cash generation | 1.7% | 3.6% | 25 of 69 |
Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).
| Region | Revenue | Share | YoY |
|---|---|---|---|
| United States | $1.8M | 59.3% | ▲ 59.6% |
| Outside the US | $1.2M | 40.7% | ▲ 92.8% |
From Therapeuticsmd, Inc.'s 10-K filed March 30, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Rubric Capital Management LP | $2.6M | 1.2M | 32.5% | 0.0% |
| Clearline Capital LP | $1.4M | 635K | 17.3% | 0.0% |
| Vanguard Capital Management LLC | $781,670 | 354K | 9.6% | 0.0% |
| Tejara Capital Ltd | $761,305 | 344K | 9.4% | ▼ 0.4% |
| ADAR1 Capital Management, LLC | $756,808 | 342K | 9.3% | ▲ 63.7% |
| Renaissance Technologies LLC | $323,984 | 147K | 4.0% | ▲ 0.3% |
| Morgan Stanley | $285,569 | 129K | 3.5% | 0.0% |
| Blackrock, Inc. | $254,470 | 115K | 3.1% | 0.0% |
| Geode Capital Management, LLC | $233,989 | 106K | 2.9% | ▼ 3.6% |
| Citadel Advisors LLC | $190,270 | 86K | 2.3% | ▲ 26.0% |
| Vanguard Fiduciary Trust Co | $141,067 | 64K | 1.7% | 0.0% |
| State Street Corp | $66,521 | 30K | 0.8% | 0.0% |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Therapeuticsmd, Inc.'s complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.
| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Thompson Tommy G Director | December 23, 2025 | Buy | 8,400 | $1.67 | $14,028 |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Next expected around November 12, 2026 estimated from the company's past filing pattern, not announced
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| Financial statements | SEC 10-K and 10-Q filings | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
New research on the companies we cover arrives in the weekly email. Free, one email a week.
